// App-Quantinova.ai

: First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).

Researchers

Presenter

  • Archana Agarwal

Principal Investigators

  • Gregory Russell Pond

  • Alexandra Drakaki

  • Jae-Lyun Lee

  • Mehmet Asim Bilen

  • Giuseppe Di Lorenzo

  • Petros Grivas

  • Moshe Chaim Ornstein

  • Pedro C. Barata

  • Shilpa Gupta

  • Syed A. Hussain

  • Catherine Curran

  • Jorge A. Garcia

  • Guru Sonpavde

Medical Centers

  • Dana-Farber Cancer Institute at St. Elizabeths Medical Center, Brighton, MA

  • McMaster University, Hamilton, ON, Canada

  • University of California, Los Angeles, Los Angeles, CA

  • Surgery, , Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of Naples Federico II, Naples, Italy

  • University of Washington Seattle Cancer Care Alliance, Seattle, WA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Tulane University, New Orleans, LA

  • University of Minnesota Masonic Cancer Research Center, Minneapolis, MN

  • University of Liverpool, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

  • Italy

  • United Kingdom

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved